Danaher Co. (NYSE:DHR) Shares Sold by Bokf Na

Bokf Na trimmed its holdings in shares of Danaher Co. (NYSE:DHR) by 4.1% in the second quarter, Holdings Channel reports. The firm owned 48,139 shares of the conglomerate’s stock after selling 2,052 shares during the period. Bokf Na’s holdings in Danaher were worth $12,028,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Jupiter Asset Management Ltd. increased its position in shares of Danaher by 0.6% during the 2nd quarter. Jupiter Asset Management Ltd. now owns 216,834 shares of the conglomerate’s stock worth $54,176,000 after purchasing an additional 1,345 shares during the last quarter. Hazlett Burt & Watson Inc. grew its position in Danaher by 4,761.9% in the 2nd quarter. Hazlett Burt & Watson Inc. now owns 1,021 shares of the conglomerate’s stock valued at $256,000 after acquiring an additional 1,000 shares in the last quarter. LPL Financial LLC grew its position in Danaher by 9.0% in the 2nd quarter. LPL Financial LLC now owns 353,217 shares of the conglomerate’s stock valued at $88,251,000 after acquiring an additional 29,043 shares in the last quarter. Biltmore Family Office LLC grew its position in Danaher by 13.1% in the 2nd quarter. Biltmore Family Office LLC now owns 1,811 shares of the conglomerate’s stock valued at $453,000 after acquiring an additional 210 shares in the last quarter. Finally, Studio Investment Management LLC grew its position in Danaher by 4.4% in the 2nd quarter. Studio Investment Management LLC now owns 1,390 shares of the conglomerate’s stock valued at $348,000 after acquiring an additional 59 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have weighed in on DHR. Wells Fargo & Company began coverage on Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price for the company. Robert W. Baird lifted their target price on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Leerink Partners lifted their target price on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Finally, Barclays lifted their price objective on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $278.94.

Danaher Price Performance

DHR stock opened at $271.98 on Thursday. The business has a 50 day moving average price of $263.20 and a 200 day moving average price of $256.22. The stock has a market cap of $196.43 billion, a price-to-earnings ratio of 46.10, a PEG ratio of 4.38 and a beta of 0.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the previous year, the business earned $2.05 earnings per share. The firm’s revenue was down 2.9% compared to the same quarter last year. Equities research analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. Danaher’s dividend payout ratio is currently 18.31%.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The disclosure for this sale can be found here. Over the last quarter, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.